Concepedia

Targeting BCL-2 as a Therapeutic Strategy for Primary <i><sup>p210</sup>BCR-ABL1</i>-positive B-ALL Cells

Michele Massimino, Elena Tirrò, Stefania Stella, Maria Stella Pennisi, Silvia Rita Vitale, Adriana Puma, Chiara Romano, Sandra Di Gregorio, M. A. Romeo, Francesco Di Raimondo,

In Vivo · 2020 · 12 citations · 28 references

DOIFull text

Open access

Abstract

BCL-2 is a key survival factor for primary Ph<sup>+</sup> B-ALL cells and its inhibition - alone or in combination with a BCR-ABL1 TKI - should be further investigated as a potential therapeutic strategy for these patients.

References

28

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

Eleni D. Lagadinou, Alexander Sach, Kevin P. Callahan et al. · Cell stem cell · 2013 · 1.3K citations · Full text

, , +8

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 758 citations

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

, , +3

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Heather A. Bradeen, Christopher A. Eide, Thomas O’Hare et al. · Blood · 2006 · 397 citations · Full text

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles et al. · Blood · 2007 · 291 citations · Full text